Topical tacrolimus and vitiligo: Our experience in sixty cases

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 6, 2007, Pages 621-625

  Baldo, A ^a   Casula, L ^a   Prizio, E ^a   Porzio, R ^a   Monfrecola, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

PUVA therapy; Tacrolimus; Ultraviolet therapy; Vitiligo, drug therapy

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BURN; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PIGMENTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VITILIGO;

EID: 38849184733     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. J Dermatol Sci 2006;41:3-10.
2. Kempt EH, Eaterman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001;34:65-7.
3. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005;65:447-59.
4. Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004;51:52-61.
5. Fain PR, Babu SR, Bennett DC, Spritz RA. HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res 2006;19:51-7.
6. Legat FJ, Armstrong CA, Ansel JC. The cutaneous neurosensory system in skin disease. Adv Dermatol 2002;18:91-109.
7. Tu C, Zhao D, Lin X. Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001;27:178-82.
8. Yildimir M, Baysal V, Inaloz HS, Can M. The role of oxidants and antioxidants in generalized vitiligo at tissue level. J Eur Acad Dermatol Venereol 2004;18:683-6.
9. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000;42:245-53.
10. Teneja A. Treatment of vitiligo. J Dermatol Treat 2002;13:19-25.
11. Nijo MD, Westerhof W, Bos JD, Bossuyt PM. The development of guidelines for the treatment of vitiligo. Arch Dermatol 1999;135:1514-21.
12. Kostovic K, Nola I, Bucan Z, Situm M. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenereol Croat 2003;11:163-70.
13. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003;71:158-62.
14. Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis 2005;16:6-21.
15. Baldo A, Prizio E, Mansueto G, Somma P, Manfrcola G. A case of chronic actinic dermatitis treated with topical tacrolimus. J Dermatol Treat 2005;16:245-8.
16. Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatol Treat 2003;14:5-16.
17. Vukmanovic-Stejic M, McQuaid A, Birch KE. Relative impact of CD4+ CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Clin Lab Invest 2005;153:750-7.
18. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789-91.
19. Evans AV, Palmer RA, Hawk JLM. Erythroderma chronic actinic dermatitis responding only to topical tacrolimus. Photodermatol Photoimmunol Photomed 2004;20:59-61.
20. Lan CG, Chen GS, Chiou MH, Wu CS, Chang CH, Yu HS. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005;153:498-505.
21. Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004;51:760-6.
22. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2005;152:183-5.
23. Lubbe J, Sorg O. Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol 2004;151:1275-6.
24. Sandrini S, Setti G, Bossini N, Maiorca P. Cancer after kidney transplantation. G Ital Nefrol 2004;26:S67-S73.
25. Marcen R, Pascual J, Tato AM, Teruel JL, Villafruela JJ, Fernandez M et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714-6.